Orfiril Long

**Orfiril Long** is a prolonged-release oral formulation of **sodium valproate**, a broad-spectrum antiepileptic drug used to treat various types of epilepsy and mania in bipolar disorder when lithium is unsuitable. Its mechanism of action is not fully elucidated but is thought to involve normalization of chemical processes between brain nerve cells, potentially through enhancement of GABAergic neurotransmission and inhibition of voltage-gated sodium channels and T-type calcium channels. Developed and authorized by **Desitin Arzneimittel GmbH** in Germany, it is available as 150 mg capsules, 500 mg minitablets, and granules, designed for once- or twice-daily dosing to maintain steady-state plasma levels.[2][3][4]

Brand names

Orfiril Long

Other names

sodium valproate2-propylpentanoate sodiumvalproic acid sodium salt